187.15
-1.46 (-0.77%)
| Previous Close | 188.61 |
| Open | 187.52 |
| Volume | 291,951 |
| Avg. Volume (3M) | 257,928 |
| Market Cap | 5,391,061,504 |
| Price / Earnings (TTM) | 62.59 |
| Price / Earnings (Forward) | 24.10 |
| Price / Sales | 17.20 |
| Price / Book | 5.11 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Profit Margin | 30.69% |
| Operating Margin (TTM) | 45.40% |
| Diluted EPS (TTM) | 3.00 |
| Quarterly Revenue Growth (YOY) | 116.30% |
| Quarterly Earnings Growth (YOY) | 423.20% |
| Total Debt/Equity (MRQ) | 0.77% |
| Current Ratio (MRQ) | 7.28 |
| Operating Cash Flow (TTM) | 123.42 M |
| Levered Free Cash Flow (TTM) | 92.96 M |
| Return on Assets (TTM) | 6.88% |
| Return on Equity (TTM) | 10.34% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Krystal Biotech, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 0.0 |
| Average | 1.00 |
|
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 12.24% |
| % Held by Institutions | 105.95% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 31 Dec 2024 | 788,460 |
| Hood River Capital Management Llc | 31 Dec 2024 | 512,726 |
| Soleus Capital Management, L.P. | 31 Dec 2024 | 358,379 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 245.00 (Jefferies, 30.91%) | Buy |
| Median | 217.00 (15.95%) | |
| Low | 189.00 (Guggenheim, 0.99%) | Buy |
| Average | 220.50 (17.82%) | |
| Total | 5 Buy, 1 Hold | |
| Avg. Price @ Call | 90.88 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 07 May 2025 | 219.00 (17.02%) | Buy | 0.000 |
| 20 Feb 2025 | 218.00 (16.48%) | Buy | 182.62 | |
| Guggenheim | 07 May 2025 | 189.00 (0.99%) | Buy | 0.000 |
| HC Wainwright & Co. | 06 May 2025 | 240.00 (28.24%) | Buy | 0.000 |
| 29 Apr 2025 | 240.00 (28.24%) | Buy | 168.06 | |
| Jefferies | 05 Mar 2025 | 245.00 (30.91%) | Buy | 180.06 |
| Cantor Fitzgerald | 20 Feb 2025 | 215.00 (14.88%) | Buy | 182.62 |
| Citigroup | 20 Feb 2025 | 215.00 (14.88%) | Hold | 182.62 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 07 May 2025 | Announcement | Krystal Biotech to Present at BofA Securities 2025 Health Care Conference |
| 06 May 2025 | Announcement | Krystal Biotech Announces First Quarter 2025 Financial and Operating Results |
| 28 Apr 2025 | Announcement | Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa |
| 24 Apr 2025 | Announcement | Krystal Biotech to Present at Upcoming Scientific Conferences |
| 17 Apr 2025 | Announcement | Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025 |
| 07 Apr 2025 | Announcement | Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer |
| 28 Feb 2025 | Announcement | Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa |
| 26 Feb 2025 | Announcement | Krystal Biotech to Present at TD Cowen 45th Annual Health Care Conference |
| 19 Feb 2025 | Announcement | Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |